This week’s episode covers the aducanumab approval. There’s also approvals in treatments for obesity and a first treatment for Plasminogen Deficiency Type 1. Plus, Moderna have sent an EUA request to extend use of their COVID-19 vaccine to those aged 12 and older.
Types of COVID-19 vaccines in the US, including those approved by the FDA under Emergency Use Authorization, as well as other investigational products currently in Phase 3 clinical trials.
The submission is based on data from the phase 2/3 TeenCOVE study, which included over 3700 US adolescents aged 12 to less than 18 years.
However, vaccines do appear to work well against this variant of the coronavirus
Research into extending the shelf life of the one-dose vaccine is ongoing
The IDSA recommends that antibody therapy should be administered to patients with mild to moderate COVID-19 at high risk for progression to severe disease.
Symptomatic and asymptomatic infection reduced by 81 percent after partial vaccination and by 91 percent after full vaccination
Lower odds of moderate and severe disease seen among health care workers eating plant-based or fish diets
Seven cases of acute myocarditis, myopericarditis identified in healthy male teens within four days after second Pfizer-BioNTech dose
Of those likely hospitalized primarily for COVID-19 during Jan.1 to March 31, 2021, 31.4 percent were admitted to ICU
